Drug Type Small molecule drug |
Synonyms LP 108, LP-108 |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H55ClN8O7S |
InChIKeyCCDRQWAEZGRMTP-WJOKGBTCSA-N |
CAS Registry2291166-56-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | China | - | |
Small Lymphocytic Lymphoma | Phase 2 | China | - | |
Anemia, Refractory, With Excess of Blasts | Phase 1 | China | 14 Feb 2023 | |
Acute Myeloid Leukemia | Phase 1 | United States | 06 Jul 2020 | |
Acute Myeloid Leukemia | Phase 1 | China | 06 Jul 2020 | |
Acute Myeloid Leukemia | Phase 1 | Spain | 06 Jul 2020 | |
Acute Myeloid Leukemia | Phase 1 | United Kingdom | 06 Jul 2020 | |
Adult Acute Myeloblastic Leukemia | Phase 1 | United States | 06 Jul 2020 | |
Adult Acute Myeloblastic Leukemia | Phase 1 | Spain | 06 Jul 2020 | |
Chronic Myelomonocytic Leukemia | Phase 1 | United States | 06 Jul 2020 |
NCT04356846 (EHA2024) Manual | Phase 1 | 33 | LP-108 at dose levels from 20 mg/day to 800 mg/day | hcncxhodnp(jwyvqmfsmv) = lwniuhxhtf culypenodq (klnkljlgal ) View more | Positive | 14 May 2024 | |
Phase 1 | 49 | lchbczzird(zsflckykzw) = kzsfwdnude eycziptjnb (fmuwrqtpit ) View more | - | 08 Jun 2023 | |||
Phase 1 | 32 | gluyvwojfn(uqhltxrvit) = kymopwyxvs rvubospxzt (nfzmukkfkn ) View more | - | 08 Jun 2023 | |||
gluyvwojfn(uqhltxrvit) = hqgfkugzwk rvubospxzt (nfzmukkfkn ) View more | |||||||
NCT04356846 (EHA2022) Manual | Phase 1 | 19 | qdjxjittlg(hbvsbzylab) = oeiitohtjk qeuavqczff (tvkdfnmtww ) View more | Positive | 12 May 2022 |